vTv Therapeutics Announces Reinitiation of Screening in CATT1 Phase 3 Trial Evaluating Potential First-in-Class Liver-Selective Glucokinase Activator Cadisegliatin for Type 1 Diabetes

Core Viewpoint - vTv Therapeutics has resumed its CATT1 Phase 3 trial for cadisegliatin, an oral treatment for type 1 diabetes, with topline data expected in the second half of 2026 [2][3]. Group 1: Trial Details - The CATT1 Phase 3 trial duration has been shortened from 12 months to 6 months through a protocol amendment, expediting the timeline for topline data without affecting key study endpoints [3][4]. - The trial will enroll approximately 150 patients aged 18 and older at 20-25 sites in the U.S., comparing two doses of cadisegliatin against a placebo [4]. - Continuous glucose monitors will be provided to all participants to assess the primary efficacy endpoint, which focuses on the incidence of level 2 and level 3 hypoglycemic events [3][4]. Group 2: Product Information - Cadisegliatin (TTP399) is a novel, liver-selective glucokinase activator being investigated as a potential first-in-class oral adjunctive treatment for type 1 diabetes [5]. - Non-clinical studies indicate that cadisegliatin enhances glucokinase activity independently of insulin, suggesting potential improvements in glycemic control [5]. Group 3: Company Overview - vTv Therapeutics Inc. is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates, with cadisegliatin as its lead program for type 1 diabetes [7].